Roche, Shire Patent Fight Escalates Over Haemophilia Drug

Sotera Employees Misappropriated Masimo Trade Secr

Sotera Employees Misappropriated Masimo Trade Secr

Roche’s patent dispute with Shire over the new haemophilia drug Hemlibra has escalated, with Shire filing a new motion in a U.S. court that Roche says aims to stop some patients from getting its medicine.

ZURICH (Reuters) - Roche’s patent dispute with London-listed Shire over the Swiss drugmaker’s new haemophilia drug Hemlibra has escalated, with Shire filing a new motion in a U.S. court that Roche says aims to stop some patients from getting its medicine.

Shire’s motion for a preliminary injunction is part of an ongoing case in which it contends Roche infringed on a key patent to develop Hemlibra, approved in November by the U.S. Food and Drug Administration.

MORE ON THIS TOPIC